Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

Teva gets exclusive 180 days to market generic antidepressant and anti-anxiety pill Lexapro

Teva Pharmaceutical Industries Ltd. Has won U.S. approval to sell the first generic version of Lexapro for depression and anxiety. Teva has been granted a 180-day exclusivity, so no other firm can market the generic medication in the United States in that timeframe, the Food and Drug Administration (FDA) said in a news release.

15 Mar 2012

First-ever compulsory license issuance in India could have implications for HIV medication

"On Monday, the Indian Patent Office effectively ended German drug maker Bayer's monopoly for its cancer drug Nexavar and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug cheaply in India," Reuters reports.

15 Mar 2012

Teva commences commercial launch of Escitalopram Oxalate Tablets

Teva Pharmaceutical Industries Ltd. announced today that it has commenced commercial launch of Escitalopram Oxalate Tablets, the Company's generic version of Forest Laboratories' depression and generalized anxiety disorder treatment, Lexapro Tablets.

15 Mar 2012

FDA approves Teva's ProAir HFA with dose counter for asthma, COPD and EIB

Teva Respiratory announced today that the U.S. Food and Drug Administration (FDA) has approved ProAir HFA with a dose counter for use in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

8 Mar 2012

Get ready for Be Medicinewise Week 2012

Building on the success of last year’s inaugural event, the week will urge all Australians to stop, think and learn more about the medicines they are using and encourage them to seek information to make better decisions about their health.

8 Mar 2012

FDA takes more time to decide on the fate of BMS & Pfizer’s joint venture anticlotting drug Eliquis

The U.S FDA have pushed back the deadline for deciding whether to approve an experimental anticlotting drug developed jointly by Pfizer Inc. and Bristol-Myers Squibb Co. The companies said late Wednesday that the Food and Drug Administration has set a new target date of June 28 for deciding whether to approve Eliquis. That’s three months later than originally scheduled.

2 Mar 2012

Glenmark Generics recalls batch of birth control pills

Drug manufacturer Glenmark Generics, announced last Friday, that it is recalling seven lots of birth control pills because in some packages, the pills were in the wrong order.

27 Feb 2012

Making a medicinewise choice between brands

Following reports the first generic version of atorvastatin will be hitting pharmacy shelves this week, NPS is urging consumers to be medicinewise when making a choice between medicine brands.

22 Feb 2012

Insulin production may persist for decades after onset of type 1 diabetes

Massachusetts General Hospital (MGH) research has found that insulin production may persist for decades after the onset of type 1 diabetes. Beta cell functioning also appears to be preserved in some patients years after apparent loss of pancreatic function. The study results appear in the March issue of Diabetes Care.

22 Feb 2012

ACAAI, Teva Respiratory partner to bring free asthma screenings nationwide

The American College of Allergy, Asthma and Immunology (ACAAI) recognizes Teva Respiratory for its continued leadership and support of important educational issues related to respiratory health, particularly under diagnosed and poorly managed asthma and exercise-induced bronchoconstriction. ACAAI announced today that they will partner again this year with Teva Respiratory to bring free asthma screenings to communities nationwide.

16 Feb 2012

Teva fourth quarter net revenues increase 28% to $5.7 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter and year ended December 31, 2011.

15 Feb 2012

FDA requests a budget of $4.5 billion to protect and promote public health

The U.S. Food and Drug Administration is requesting a budget of $4.5 billion to protect and promote the public health as part of the President's fiscal year (FY) 2013 budget – a 17 percent increase over the FDA enacted budget for FY 2012.

14 Feb 2012

Proposed intellectual property agreement between E.U., India could affect generic drug exports, advocacy groups say

The Independent examines how "the cheap supply of antiretroviral drugs to people with AIDS across the world could be choked by an 'intellectual property' deal ... being negotiated on Friday at the 12th E.U.-India summit in New Delhi between the President of the European Commission, José Manuel Barroso, and the Indian Prime Minister Dr. Manmohan Singh."

13 Feb 2012

FDA lays guidelines for “biosimilar” biotech drugs

The proposed rules, issued on Thursday, require studies showing that the generic copies are “highly similar” to the originals, but there are several ways that might be proven. Because of their complexity, generic copies of biotech drugs - first introduced in the 1980s - are known as “biosimilars.” The worldwide market for copies of biotech medicines will grow to $3.7 billion by 2015, from just $243 million in 2010, as more than 30 branded biologics with sales of $51 billion lose patent exclusivity, according to market analysis firm Datamonitor.

12 Feb 2012

Viewpoints: Komen's retreat; Romney's selected support of Medicare cuts; Heritage refuses blame for individual mandate

A group like Komen only has the quality service it provides and goodwill garnered over the years to encourage donations and support. Its trademark pink is not as bold as before. For the moment, it seems drab and faded.

6 Feb 2012

MTR technique indicates that COPAXONE therapy results in tissue repair in RRMS patients

Researchers utilizing an advanced magnetic resonance imaging (MRI) technology to characterize and chart the evolution of MS lesions found that relapsing-remitting multiple sclerosis (RRMS) patients treated with COPAXONE (glatiramer acetate injection) experienced significantly increased magnetization transfer ratio.

4 Jan 2012

J&J will not join Medicines Patent Pool; Company's pharma head says mechanism could 'cause disaster'

Pharmaceutical company "Johnson & Johnson has rejected calls to offer patent rights on its HIV medicines to generic drug companies through a" Medicines Patent Pool, created to promote low-cost antiretroviral drugs in low-income countries and the development of new drug combinations and formulations, the Financial Times reports.

4 Jan 2012